Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Y-TR1 SMCC [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.00 ug/mL	Positive CD26 expression (CD26+++/++)
Method Description	Viability assay of Jurkat cells incubated for 72 h with ADC.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Y-TR1 GMBS [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.00 ug/mL	Positive CD26 expression (CD26+++/++)
Method Description	Viability assay of Jurkat cells incubated for 72 h with ADC.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Y-TR1 SPDP [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	35.00 ug/mL	Positive CD26 expression (CD26+++/++)
Method Description	Viability assay of Jurkat cells incubated for 72 h with ADC.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

References

Ref 1	Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis. Cancers (Basel). 2019 Aug 8;11(8):1138. doi: 10.3390/cancers11081138.